Cancer Pain Management — Part 2: The Analgesic Ladder and Non-Opioid Pharmacotherapy

The Analgesic Ladder: Framework and Modern Adaptations

Original Three-Step Ladder

The three-step analgesic ladder, first published in 1986 and updated in subsequent editions, provides a systematic framework for the pharmacological management of cancer pain based on pain intensity and response to treatment. When applied correctly, this approach achieves adequate pain relief in approximately 70% to 90% of cancer patients.¹

Step 1 — Mild pain (NRS 1–3): Non-opioid analgesic (acetaminophen or NSAID) with or without an adjuvant analgesic

Step 2 — Mild to moderate pain (NRS 4–6), or pain not adequately controlled by Step 1: Weak opioid (codeine, tramadol) with or without a non-opioid analgesic, with or without an adjuvant analgesic

Step 3 — Moderate to severe pain (NRS 7–10), or pain not adequately controlled by Step 2: Strong opioid (morphine, oxycodone, hydromorphone, fentanyl, methadone) with or without a non-opioid analgesic, with or without an adjuvant analgesic

At every step, adjuvant analgesics should be considered when indicated by the pain mechanism (e.g., neuropathic pain, bone pain). Non-pharmacological strategies should accompany pharmacological treatment throughout.

Modern Modifications and Critiques

The traditional three-step ladder has been subject to significant discussion and modification in contemporary practice:²

Bypassing Step 2: Multiple professional societies now endorse the option of starting directly at Step 3 with low-dose strong opioids for moderate pain, rather than using weak opioids as an intermediate step. Evidence supporting this approach includes:

• Weak opioids have ceiling effects that limit analgesic efficacy
• Codeine requires CYP2D6 metabolism to morphine for efficacy, with significant pharmacogenomic variability (5–10% of Caucasians and up to 30% of some African and Middle Eastern populations are poor metabolizers)
• Low-dose strong opioids (e.g., morphine 5–10 mg oral every 4 hours, or low-dose extended-release morphine 15–30 mg daily) provide equivalent or superior analgesia with a similar side-effect profile
• Major guidelines now include “low-dose strong opioid” as an alternative to Step 2 weak opioids

Addition of a “Step 4” — Interventional approaches: Some authors and guidelines propose a fourth step for pain refractory to systemic pharmacotherapy, encompassing interventional procedures such as nerve blocks, neuraxial drug delivery, and neuroablative techniques. These approaches should not be reserved only as a “last resort” but should be considered earlier when specific pain syndromes are amenable to interventional treatment (e.g., celiac plexus block for pancreatic cancer pain).

Bidirectional movement: The ladder should not be viewed as strictly unidirectional. Patients may move up or down steps as their pain changes with disease progression, treatment response, or new interventions. For example, successful radiation of a painful bone metastasis may allow de-escalation of opioid therapy.

Mechanism-based approach: Contemporary pain management increasingly emphasizes a mechanism-based approach alongside the ladder framework. Identifying the predominant pain mechanism (nociceptive, neuropathic, mixed) guides adjuvant selection regardless of the ladder step.

Five Principles of Cancer Pain Pharmacotherapy

The fundamental principles of the analgesic approach, as articulated in the original framework and maintained in updated guidelines, are:¹

1. By mouth: Use the oral route whenever possible. Alternative routes (transdermal, subcutaneous, intravenous, rectal) should be considered when the oral route is not available or appropriate.

2. By the clock: Analgesics for persistent cancer pain should be administered on a fixed schedule (around-the-clock), not on an as-needed (“PRN”) basis only. Around-the-clock dosing maintains steady-state plasma levels and prevents the cycle of pain recurrence and re-dosing.

3. By the ladder: Analgesic selection should follow the stepwise approach based on pain intensity and prior treatment response.

4. For the individual: Dosing must be individualized. There is no standard dose for opioid analgesics in cancer pain — the right dose is the dose that relieves pain without intolerable side effects.

5. Attention to detail: Thorough monitoring of efficacy, side effects, and patient adherence, with prompt adjustment of the regimen as needed.

Step 1: Non-Opioid Analgesics

Acetaminophen (Paracetamol)

Acetaminophen is a centrally-acting analgesic with antipyretic properties but no clinically significant anti-inflammatory effect. It is the first-line non-opioid analgesic for mild cancer pain and is commonly used as a co-analgesic alongside opioids at all ladder steps.³

Dosing

Key Considerations in Cancer Patients

• Hepatic metastases: Patients with extensive hepatic metastases may have impaired acetaminophen metabolism; use reduced doses (2000 mg/day maximum) and monitor LFTs
• Hepatotoxicity risk: Compounded by malnutrition (depleted glutathione stores), chronic alcohol use, and concomitant hepatotoxic medications
• Hidden sources: Many combination opioid products contain acetaminophen (e.g., acetaminophen/codeine, acetaminophen/oxycodone, acetaminophen/hydrocodone); total daily acetaminophen from all sources must be tracked
• Fever masking: Antipyretic effect may mask febrile neutropenia in immunocompromised patients; this must be weighed against analgesic benefit
• Combination with opioids: Evidence for the additive analgesic benefit of acetaminophen when added to strong opioids is limited and mixed; however, it remains commonly used and may provide a modest opioid-sparing effect

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thereby providing analgesic, anti-inflammatory, and antipyretic effects. They are particularly effective for bone pain (which has a significant prostaglandin-mediated component) and inflammatory pain. NSAIDs may be used alone for mild pain or as co-analgesics with opioids at all ladder steps.⁴

NSAID Dosing Table

Risk Stratification and NSAID Selection in Cancer Patients

Cancer patients frequently have multiple risk factors that complicate NSAID use. A careful risk-benefit assessment should precede NSAID initiation, and the lowest effective dose for the shortest duration necessary should be employed.⁵

Gastrointestinal risk:

Renal considerations:

• Avoid NSAIDs in patients with creatinine clearance below 30 mL/min
• Use with caution (lowest dose, limited duration, monitoring) if creatinine clearance 30–60 mL/min
• Risk is amplified by concurrent nephrotoxic agents (cisplatin, aminoglycosides, contrast dye), dehydration, and hypercalcemia — all common in cancer patients
• All NSAIDs, including COX-2 selective agents, carry renal risk

Cardiovascular considerations:

• All NSAIDs (except low-dose aspirin) are associated with increased cardiovascular thrombotic risk
• Naproxen may have the lowest cardiovascular risk among non-selective NSAIDs
• COX-2 selective agents (celecoxib) carry cardiovascular risk; use lowest effective dose
• Avoid NSAIDs in patients with recent myocardial infarction, unstable angina, decompensated heart failure, or uncontrolled hypertension

Hematological considerations (particularly relevant in oncology):

• Non-selective NSAIDs inhibit platelet aggregation and prolong bleeding time; avoid in patients with thrombocytopenia (platelets below 50,000/mcL is a commonly used threshold, though some experts use 100,000/mcL)
• COX-2 selective agents (celecoxib) have minimal platelet effects and may be preferred in patients with thrombocytopenia or receiving anticoagulation, though they are not free of bleeding risk
• Avoid NSAIDs in patients with active bleeding, coagulopathy, or planned invasive procedures

Corticosteroid co-administration:

• Concurrent corticosteroid and NSAID use significantly increases GI ulcer and bleeding risk
• If both are needed, add a PPI

Step 2: Weak Opioids

Overview and Current Role

Step 2 of the analgesic ladder employs weak opioids — codeine and tramadol — for mild-to-moderate cancer pain that is not adequately controlled by non-opioid analgesics alone. As noted above, contemporary practice increasingly supports bypassing Step 2 in favor of low-dose strong opioids, and several guidelines now include this as an acceptable alternative. However, weak opioids retain a role in specific clinical situations, particularly in settings where access to strong opioids may be limited, and they remain part of the standard framework.⁶

Codeine

Codeine is a prodrug that requires hepatic conversion via CYP2D6 to morphine for its analgesic effect. Approximately 10% of the administered codeine dose is converted to morphine. This metabolism is subject to significant pharmacogenomic variability.

Dosing

Limitations and Cautions

• CYP2D6 polymorphism: Poor metabolizers (5–10% of Caucasians, up to 30% of some populations) will have minimal analgesic effect from codeine. Ultrarapid metabolizers (1–2% of Caucasians, up to 10% of some populations) may experience exaggerated opioid effects and toxicity, including respiratory depression. Pharmacogenomic testing for CYP2D6 should be considered when available.
• Ceiling effect: Analgesic efficacy plateaus at approximately 60 mg per dose; higher doses increase side effects without proportional analgesic benefit
• Constipation: Codeine causes constipation at rates higher than other opioids relative to its analgesic potency
• Drug interactions: CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, duloxetine) reduce codeine’s conversion to morphine and diminish analgesia
• Renal impairment: Active metabolites (morphine-6-glucuronide) accumulate in renal impairment; use with caution or avoid in patients with creatinine clearance below 30 mL/min
• Not recommended as first-choice weak opioid in current practice due to pharmacogenomic variability and availability of alternatives

Tramadol

Tramadol is a synthetic analgesic with a dual mechanism of action: weak mu-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake. This dual mechanism may offer theoretical advantages for mixed nociceptive-neuropathic pain.

Dosing

Limitations and Cautions

• Seizure risk: Tramadol lowers the seizure threshold; avoid in patients with epilepsy or history of seizures, and in patients receiving other seizure-threshold-lowering medications. Risk increases at doses above 400 mg/day.
• Serotonin syndrome risk: Due to serotonin reuptake inhibition, tramadol should be used with caution or avoided in combination with other serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, ondansetron). Serotonin syndrome is a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular excitability.
• CYP2D6 metabolism: Like codeine, tramadol requires CYP2D6 for conversion to its active metabolite (O-desmethyltramadol, M1), which has higher opioid receptor affinity. Poor metabolizers may have reduced analgesic effect. Ultrarapid metabolizers may be at higher risk of adverse effects.
• Ceiling effect: Limited analgesic efficacy for moderate-to-severe cancer pain; should not delay transition to strong opioids when pain is not adequately controlled
• Renal impairment: Reduce dose and extend dosing interval with creatinine clearance below 30 mL/min (immediate-release: 50–100 mg every 12 hours, maximum 200 mg/day); avoid extended-release formulation in severe renal impairment
• Hepatic impairment: Reduce dose in cirrhosis (immediate-release 50 mg every 12 hours); avoid extended-release formulation in severe hepatic impairment

Transitioning from Step 2 to Step 3

Patients should be transitioned from weak opioids to strong opioids when:

• Pain is not adequately controlled at maximum doses of the Step 2 agent
• The patient requires more than 4–6 rescue doses per day in addition to the scheduled weak opioid
• Pain intensity persistently exceeds the patient’s pain goal despite optimized Step 2 therapy
• Dose-limiting side effects of the weak opioid preclude further titration

When transitioning, calculate the approximate equianalgesic dose of the strong opioid based on the current weak opioid dose, apply a 25–50% dose reduction for incomplete cross-tolerance, and ensure breakthrough medication is prescribed. Detailed opioid conversion methods are addressed in Part 3.

Combining Non-Opioid and Opioid Analgesics: The Multimodal Approach

At all steps of the analgesic ladder, a multimodal approach combining agents with different mechanisms of action is recommended to optimize analgesia while potentially reducing opioid requirements and associated side effects.

Evidence for Multimodal Combinations

Practical Prescribing Principles

• Always consider a non-opioid analgesic as a component of the regimen unless contraindicated
• Select the non-opioid based on pain mechanism (NSAIDs for bone/inflammatory pain; acetaminophen as a general co-analgesic) and patient risk profile
• Add adjuvant analgesics based on pain mechanism (anticonvulsants or antidepressants for neuropathic pain; corticosteroids for bone, visceral, or nerve compression pain; see Part 4)
• Reassess regularly whether each component of the multimodal regimen is contributing to pain relief
• When pain is well-controlled, consider de-escalation (reducing opioid dose while maintaining non-opioid and adjuvant agents)

References